Zafgen Halts Clinical Trial Of Obesity Drug Following Death Of Second Patient

The death of another patient participating in the late-stage trial of Zafgen's obesity drug has prompted the FDA to order for the complete hold of the study. The drug beloranib is being tested in patients with the genetic disorder Prader-Willi syndrome.